, Tracking Stock Market Picks
Enter Symbol:
Amarin Corporation Plc (AMRN) [hlAlert]

Neutral AMRN
down 30.76 %

Amarin Corporation Plc (AMRN) downgraded to Neutral by Wedbush

Posted on: Wednesday,  Oct 3, 2012  8:25 AM ET by Wedbush

Wedbush rated Neutral Amarin Corporation Plc (NASDAQ: AMRN) on 10/03/2012. Previously Wedbush rated Outperform Amarin Corporation Plc (NASDAQ: AMRN) on
04/25/2011., when the stock price was $17.29. Since then, Amarin Corporation Plc has lost 30.77% as of 10/03/2012's recent price of $11.97.
If you would have followed the previous Wedbush 's recommendation on AMRN, you would have lost 30.76% of your investment in 527 days.

Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical company with a focus on cardiovascular disease. Amarin has a range of clinical and preclinical stage compounds to treat central nervous system (CNS) disorders, including Huntington?s disease, myasthenia gravis and Parkinson?s disease. Its cardiovascular programs and non-core CNS programs include AMR101, EN101, Sublingual Apomorphine and AMR 103. The Company's subsidiaries include Amarin Neuroscience Limited, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc, Amarin Finance Limited and Ester Neurosciences Limited.

Wedbush is Headquartered in Los Angeles, California with over 90 offices and more than 125 correspondent offices, our commitment to providing relentless, customized service is the foundation of our consistent growth. We deliver superior investment ideas and products through exceptional customer care, financial security, continuity and advanced technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/3/2012 8:25 AM Hold
as of 12/31/2012
1 Week   
1 Month   
3 Months down  -4.77 %
1 YTD up  59.81 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/25/2011 9:25 AM Buy
17.29 18.00
12/29/2010 9:25 AM Buy
8.06 10.00
7/20/2010 9:25 AM Buy
2.25 5.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy